TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01879670

Intervention type: DEVICE
Intervention: CircuLite Synergy left ventricular assist device
Study: NCT03815396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-101/rhAAT-Fc
Description: INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-101/rhAAT-Fc
Description: INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).
Study: NCT04136080

Intervention type: OTHER
Group type: OTHER
Intervention: vasopressors
Description: control the mean arterial pressure with vasopressors

Intervention type: OTHER
Group type: OTHER
Intervention: vasopressors
Description: control the mean arterial pressure with vasopressors
Study: NCT00489840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile suspension 15 mg
Description: anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate
Description: anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.
Study: NCT01581710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast to placebo
Description: Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to montelukast
Description: Subjects will receive matching placebo. Each treatment period consists of 2 weeks
Study: NCT01276951

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Food Anamnesis
Description: With the aim of learning about the eating habits, it will be made based on a food intake recall the last 24 hours, taking into account that is not preceded by a special food day (sundays, holidays, celebrations). For more accurately calculate nutrient ingested food, modules will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Samples: serological tests and culture of mononuclear cells
Description: At admission and at the end of the study will be obtained after 12 hours of fasting, 8 mL of blood in a dry tube without anticoagulant and 30 mL of blood in heparin tubes, properly labeled with the code assigned to the participant. The sample will be used to determine the complete lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and VLDL cholesterol), State of oxidation of low density lipoprotein (oxLDL) and mononuclear cell culture. The remaining serum was kept at -20°C for use if is required repeat any study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Samples: serological tests and culture of mononuclear cells
Description: At admission and at the end of the study will be obtained after 12 hours of fasting, 8 mL of blood in a dry tube without anticoagulant and 30 mL of blood in heparin tubes, properly labeled with the code assigned to the participant. The sample will be used to determine the complete lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and VLDL cholesterol), State of oxidation of low density lipoprotein (oxLDL) and mononuclear cell culture. The remaining serum was kept at -20°C for use if is required repeat any study.
Study: NCT00474760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity
Study: NCT01206166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olimel (5.7%E / N9E)
Description: OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
Study: NCT02434978

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supplementary endoscopy with doppler-guided therapy
Description: Patients randomized to supplementary doppler-guided therapy undergo repeat endoscopy with doppler evaluation within 24 hours from the primary endoscopy. At the control endoscopy the ulcer base is examined using a doppler device. If active doppler flow is demonstrated the ulcer is treated with a thermal probe until a control doppler-scan is negative. All patients are observed for rebleeding at a specialized GI-bleeding unit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV. PPI
Description: All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV. PPI
Description: All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic treatment at primary endoscopy
Description: All patients are initially treated with endoscopic therapy using a minimum of two different treatment modalities. The primary endoscopy is performed wihtin 24 hours from time of admission to hospital

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopic treatment at primary endoscopy
Description: All patients are initially treated with endoscopic therapy using a minimum of two different treatment modalities. The primary endoscopy is performed wihtin 24 hours from time of admission to hospital
Study: NCT01216748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quiet breathing
Description: Subjects were instructed to breath normally at room air.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypocapnic Hyperventilation
Description: hypocapnic hyperventilation, the subjects were instructed to breathe fast and deep until their end-tidal pCO2 fell to 30 mmHg, corresponding to a systemic pH increase of about 0.1 pH units.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypercapnic Hyperventilation
Description: For hypercapnic hyperventilation, a modification of a previously described procedure (15). While monitoring SaO2 using pulse oximetry and end-tidal CO2 by mass-spectrometry on a breath by breath basis, CO2 was bled into the inspired air to achieve an end-tidal pCO2 of at least 55 mmHg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eucapnic hyperventilation
Description: For eucapnic hyperventilation, the subjects were instructed to increase their ventilation to the highest level of ventilation recorded in the previous two hyperventilation maneuvers, while CO2 was bled into the inspired air to maintain end-tidal pCO2 at 40 mmHg.
Study: NCT01276951

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Samples: serological tests and culture of mononuclear cells
Description: At admission and at the end of the study will be obtained after 12 hours of fasting, 8 mL of blood in a dry tube without anticoagulant and 30 mL of blood in heparin tubes, properly labeled with the code assigned to the participant. The sample will be used to determine the complete lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and VLDL cholesterol), State of oxidation of low density lipoprotein (oxLDL) and mononuclear cell culture. The remaining serum was kept at -20°C for use if is required repeat any study.
Study: NCT03911479

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Description: Bariatric Surgery - convencionals Roux-en-Y gastric bypass (RYGB) and vertical gastrectomy (Sleeve; SG)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bariatric Surgery
Description: Bariatric Surgery - convencionals Roux-en-Y gastric bypass (RYGB) and vertical gastrectomy (Sleeve; SG)
Study: NCT00758433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zucapsaicin
Description: Civamide patch 0.0075% q.d. 24 hours for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zucapsaicin
Description: Civamide patch 0.0150% q.d. 24 hours for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Placebo patch q.d. 24 hours for 7 days
Study: NCT02981706

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriovenous Fistula (AVF)
Description: The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous fistula, or connection between a native artery and vein.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriovenous Graft (AVG)
Description: The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous graft, or synthetic connection between a native artery and vein.
Study: NCT01970748

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal variceal ligation
Description: Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
Study: NCT03967717

Intervention type: OTHER
Intervention: Characterization of parameters of medical history, examination and diagnostics.
Description: Patients receive standard of care diuretics. The study only collects data to characterize parameters of medical history, examination and diagnostics.
Study: NCT01257074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir 50mg/g
Description: Cream, dose 5 times daily during 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penciclovir 10mg/g
Description: Cream, dose 5 times daily during 5 days
Study: NCT05913258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser system (Doctor smile, Pluser, Italy)
Description: The Er:YAG laser offers a virtually painless alternative to conventional methods of caries removal, and its adoption in clinical practice could greatly reduce children's fear of going to the dentist. Caries removal is one of the leading reasons for dentist visits among children, and many children become fearful at the mere thought of a drill touching their teeth, before they even hear the sound. Laser caries removal could go a long way toward eliminating children's fear of going to the dentist; it is virtually painless, and most children are able to get through the entire procedure without needing local anesthesia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Master Torque high/low-speed air rotor handpiece (KaVo Dental, Charlotte, North Carolina, USA)
Description: Mechanical removal of carious lesions with a rotating handpiece and bur instruments is the most often used approach for treating dental caries because it is cost-effective, timesaving, and simple. However, these procedures have many drawbacks, including the potential for removing healthy tooth structures, vibration and noise, which can cause the patient anxiety and pain, thus necessitating local anesthesia.
Study: NCT01817829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 500 mg oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02033187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing
Description: Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-chlorhexidine bathing
Description: Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
Study: NCT00222326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training and lifestyle modification
Study: NCT04769635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Description: All studied patients were received CPAP therapy with average cumulative adherence ⩾4 h/day of \>70% nights \[380\] obtained from device download with AHI\<5 /hr
Study: NCT01276951

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Samples: serological tests and culture of mononuclear cells
Description: At admission and at the end of the study will be obtained after 12 hours of fasting, 8 mL of blood in a dry tube without anticoagulant and 30 mL of blood in heparin tubes, properly labeled with the code assigned to the participant. The sample will be used to determine the complete lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and VLDL cholesterol), State of oxidation of low density lipoprotein (oxLDL) and mononuclear cell culture. The remaining serum was kept at -20°C for use if is required repeat any study.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Samples: serological tests and culture of mononuclear cells
Description: At admission and at the end of the study will be obtained after 12 hours of fasting, 8 mL of blood in a dry tube without anticoagulant and 30 mL of blood in heparin tubes, properly labeled with the code assigned to the participant. The sample will be used to determine the complete lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and VLDL cholesterol), State of oxidation of low density lipoprotein (oxLDL) and mononuclear cell culture. The remaining serum was kept at -20°C for use if is required repeat any study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of cytokine production
Description: We will be used the supernatant of mononuclears cell culture to quantify the production of interleukin one beta, interleukin two, tumor necrosis factor alpha by ELISA with commercially available kits for this purpose.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of cytokine production
Description: We will be used the supernatant of mononuclears cell culture to quantify the production of interleukin one beta, interleukin two, tumor necrosis factor alpha by ELISA with commercially available kits for this purpose.
Study: NCT01849055

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023703
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Administered orally
Study: NCT00475501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: 125 mg, i.m. injection, once/week, for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: 125 mg, i.m. injection, once/week, for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: 5 mg, oral, once/day, for 52 weeks
Study: NCT00305643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Initial dose of 750-1500 mg/m\^2 orally twice a day for each 21 day cycle.
Study: NCT00475501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: 5 mg, oral, once/day, for 52 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00570219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproate
Description: Valproate 20 mg/kg per day for 2 weeks, reduction during week 3. Conversion of benzodiazepines to an equivalent dose of diazepam (maximum 80 mg per day). Dosage reduced 10 mg daily until 40 mg per day. Reduction then continued 5 mg daily.
Study: NCT01239316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT01278888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterolateral thoracotomy
Description: Standard anterolateral thoracotomy
Study: NCT00305643

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Initial dose of 750-1500 mg/m\^2 orally twice a day for each 21 day cycle.
Study: NCT01278888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterolateral thoracotomy
Description: Standard muscle sparing posterolateral thoracotomy
Study: NCT00305643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg given orally twice a day for each 21 day cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Some patients may undergo radiation therapy 5 days a week for 5-6 weeks, and receive oral capecitabine twice daily 5 days a week. Following completion of radiotherapy, patients may continue oral capecitabine once daily on days 1-14.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Radiation Therapy
Description: Some patients may undergo radiation therapy 5 days a week for 5-6 weeks, and receive oral capecitabine twice daily 5 days a week. Following completion of radiotherapy, patients may continue oral capecitabine once daily on days 1-14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo twice daily on days 1-21
Study: NCT04534439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX-115
Description: oral administration of APX-115 400mg capsule once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of APX-115-matching placebo 400mg capsule once daily for 12 weeks
Study: NCT01278888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS
Description: Standard video assisted thoracic surgery, no use of rib-spreader.
Study: NCT01496430

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Study: NCT00127062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxford street
Description: 2 h walk around Oxford street

Intervention type: OTHER
Group type: OTHER
Intervention: Oxford street
Description: 2 h walk around Oxford street

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyde park
Description: 2 h walk around Hyde park
Study: NCT01278888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterolateral Thoracotomy
Description: Standard anterolateral thoracotomy
Study: NCT03688659

Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin and gentamycin
Description: intravenous
Study: NCT00739518

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Neurological MRI with new technology evaluation. The new technology may involve software or MRI scanning sequences. This is a long term research study that focuses on new technology that is constantly being created.
Study: NCT02827617

Intervention type: DRUG
Intervention: Ibrutinib
Description: Treatment with ibrutinib 420 mg quaque die in the clinical practice
Study: NCT04225780

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose IL-2 and ganciclovir
Description: If patients are eligible, which CMV-DNA are more than 10\^3 copies, it will be randomly distributed in low-dose IL-2 and ganciclovir group, or ganciclovir group. Low-dose IL-2 is defined as 1 million IU per day subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 and ganciclovir
Description: If patients are eligible, which CMV-DNA are more than 10\^3 copies, it will be randomly distributed in low-dose IL-2 and ganciclovir group, or ganciclovir group. Low-dose IL-2 is defined as 1 million IU per day subcutaneously.
Study: NCT01811407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Precommitment announcement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Precommitment announcement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Results announcement

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Walking program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking program
Study: NCT06335446

Intervention type: OTHER
Intervention: Novel mapping algorithm
Description: Signals will be collected during the catheter ablation. These signals STAR maps will be created post procedure and these will be compared to the conventional maps used during the atrial tachycardia ablation. This will be used to validate the STAR maps created.
Study: NCT00127062

Intervention type: OTHER
Group type: OTHER
Intervention: Hyde park
Description: 2 h walk around Hyde park
Study: NCT02645058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIRS
Description: Treatment by ureterorenoscopy (RIRS) and laser lithotripsy
Study: NCT03902236

Intervention type: OTHER
Intervention: Balance
Description: Balance will be assessed with functional reach test in cystic fibrosis, bronchiectasis and healthy groups Functional Reach measures the maximum distance a person can reach forward, the distance of the person standing at the edge of the wall with a 90-degree shoulder flexion and the maximum distance to the front of the thumb will be noted.
Study: NCT04410055

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sitting
Description: We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)